Aim/Background: Tuberculosis is a serious health issue across the world. Various bioactive molecules show the affects against Multidrug-resistant tuberculosis (MDR-TB). There are various standard drugs developed against Mycobacterium for its treatment. But, the pathogen of tuberculosis is developing resistance towards the various standard. The present study was aimed to determine the effect of Beilschmiedia phytoconstituents against different protein targets of Mycobacterium tuberculosis (MTB). Materials and Methods: Proteins and ligands were retrieved from RCSB PDB and Knapsack 3D database. Data of active site of proteins were taken from Protein Data Bank Japan (PDBj) (https:// pdbj.org/) and computed atlas of surface topography of proteins (CASTp) (http://sts. bioe.uic.edu/castp/index.html). Molecular docking was performed by AutoDock tool 4.0. Results: The Beilschmie flavonoid A and Beilschmie flavonoid B, Beilschmiedic Acid A and B were virtually screened for their free binding energy against various protein targets of MTB. Flavonoids showed binding with target proteins and exhibited well promising inhibition of MTB target proteins. There were some specific targets to which particular ligand binds strongly. Conclusion: We found that compounds of Beilschmiedia act in fatty acid degradation pathway at their various steps.
INTRODUCTION
Tuberculosis (TB) is a serious health issue across the world. It is an infectious disease caused by the bacillus Mycobacterium tuberculosis (MTB). Disease called "Consumption" in past because the way it would consume from within anyone who became infected. 1 About 64% TB patients are from countries like India, Indonesia, China, Philippines, Pakistan, Nigeria and South Africa and India tops the highest number of TB cases followed by the other six countries respectively. 2 MTB that causes tuberculosis develops resistance to antimicrobial drugs used to cure disease this condition is known as drug-resistance TB. 3 There are two main types of drug-resistant TB i.e., Multidrugresistant TB (MDR-TB) and Extensively drug-resistant TB (XDR-TB). Multidrugresistant TB (MDR-TB) is a type of TB that does not respond to at least isoniazid and rifampicin, which is the most powerful anti-TB drugs. 4 Drug resistance may be because of inadequate treatment or direct transmission of drug-resistant bacillus from one person to another. 5 The major health problem threatens the progress made in TB control worldwide. There is an urgent need to develop novel anti-tuberculosis agents, adjunct treatments and to improve immunity. In addition, most of the anti-TB drugs currently target metabolic reactions and proteins that are critical for the proliferation of M. tuberculosis. 6 In recent years, there has been an increasing interest in natural product based medicines from plant origin. 7 These plants are an important source of bioactive secondary metabolites, which have enormous therapeutic potential. 8 Therefore, to overcome the serious issue of MDR-TB, plant metabolites can used. In this context, we will study the plant metabolites of two different species of Beilschmiedia i.e., Beilschmiedia anacardioides and Beilschmiedia zenkeri. Beilschmiedia anacardioides and Beilschmiedia zenkeri is an evergreen tree, distributed throughout Central Africa. The fruits of Beilschmiedia zenkeri are appetite stimulants. 9 Beilschmiedia anacardioides stem bark cure uterine tumours, rubella, female genital infections and rheumatisms. 10 The stem bark of B. zenkeri consists of four new methoxylated flavonoid derivatives, (2S, 4R)-5, 6, 7-trimethoxyflavan-4-ol, (2S, 4R)-4, 5, 6, 7-tetramethoxyflavan, beilschmie flavonoid A and beilschmie flavonoid B and with seven known compounds. They showed antibacterial effect against three strains of bacteria, Pseudomonas agarici, Bacillus subtilis and Streptococcus minor and for their antiplasmodial activity against Plasmodium falciparum, chloroquine-resistant strain W2.
11 Molecular docking is a computer simulation procedure to predict the conformation of a receptor-ligand complex, where the receptor is usually a protein or a nucleic acid molecule (DNA or RNA) and the ligand is either a small molecule or another protein. Objective of current study is to find the potential protein targets of MTB form docking.
MATERIALS AND METHODS

Retrieval of 3D Structure of Protein and Ligands
Molecular docking was performed using AutoDock 4.0 software. 12 Different target sites were selected by getting locus information of organism from target databases; 27 different targeted proteins were selected for docking Table 1 . Their 3D structure were retrieved from RCSB PDB in pdb (PDB (TEXT)) file format. 13 Active sites of proteins were identified from Protein Data Bank Japan (PDBj) (https://pdbj.org/) 14 and Computed Atlas of Surface Topography of proteins (CASTp) (http://sts. bioe.uic.edu/castp/index.html). 15 The ligands retrieved from KNApSAcK-3D (http://knapsack3d.sakura. ne.jp/). The Ligand 3-D structures saved in 'mol' file. Files are converted in.pdb format, using Open babel Software version 2.3.2a 16 
RESULTS
Docking of MTB targets with beilschmie flavonoid A
In silico molecular docking studies was performed using MTB protein targets with beilschmie flavonoid A (B. zenkeri). 13 target proteins shows interaction with beilschmie flavonoid A. All interactions with their binding energy are shown in 
Docking of MTB Targets with Beilschmiedic acid A
Beilschmiedic acid A and beilschmiedic acid B was obtained from stem bark of B. anacardioides plant. 23 target proteins of MTB interact with beilschmiedic acid. All the interactions with binding energy are shown in Table 5 . The results showed that all the docked ligands had binding energy ranging between -1.71 Kcal/mol The conformations of the docked compounds of Beilschmiedia zenkeri and Beilschmiedia anacardioides fits exactly into the active site region of receptor.
To evaluate the mechanism of the compounds with their respective targeted proteins we constructed the predicted pathway for drug-target mechanism Figure 3 . We found that all the compounds act in fatty acid degradation pathway at their various steps. Beilschmie flavonoid A acts on rubredoxin enzyme, which acts as electron carrier in ω-Hydroxylation of fatty acids, beilschmie flavonoid B acts on echA6 enzyme, involved in β-oxidation of fatty acid metabolism and beilschmiedic acid A and B acts on synthesis of fatty acid synthase (FAS II), which is involved in synthesis of mycolic acid present in cell anacardioides and their use as bioactive molecules. The findings suggest that in future these compounds could be developed as a lead compounds for designing of novel drugs against MDR-TB.
CONCLUSION
Structure based computational exploration have been applied to predict interaction of beilschmie flavonoid A, beilschmie flavonoid B, beilschmiedic acid A and beilschmiedic acid B with MDR-TB targets. Virtual screening strategies are time-saving, cost-effective and productive alternatives in the drug discovery process.
In silico molecular docking studies clearly demonstrated binding activity of ligands with protein targets of Mycobacterium tuberculosis which warrants further studies for the development of potent inhibitors in the treatment of MDR-TB. Results clearly indicate that the phytochemicals from Beilschmiedia species as Mycobacterium tuberculosis inhibitors. Hence we conclude that secondary metabolites from Beilschmiedia species could be potential lead molecules against MDR-TB which can be further evaluated through in vivo studies.
• There is a continuous need for the development of new drug molecules with newer targets and with an alternative mechanism of action due to increasing drug resistance of Mycobacterium tuberculosis to the currently used drugs. This study indicates the importance of phytoconstituents of Beilschmiedia species i.e., B. zenkeri and B. anacardioides and their use as bioactive molecules. The findings suggest that in future these compounds could be developed as a lead compounds for designing of novel drugs against MDR-TB.
